Showing 9491-9500 of 20370 results for "".
- Ramucirumab Plus Docetaxel Shows Phase II Activity in Gastric Cancerhttps://reachmd.com/news/ramucirumab-plus-docetaxel-shows-phase-ii-activity-in-gastric-cancer/2487782/Key Takeaways The combination was associated with measurable activity, with disease control reported in nearly three quarters of patients. The findings came from a multicenter, single-arm phase II trial of 35 patients who were refractory or intolerant
- IVUS Guidance In Complex High-Risk PCI Fails To Lower TVFhttps://reachmd.com/news/ivus-guidance-in-complex-high-risk-pci-fails-to-lower-tvf/2487783/Key Takeaways Target-vessel failure occurred more often numerically with IVUS guidance, and a lower primary-endpoint risk was not reported with that strategy. IVUS-guided procedures lasted longer and more often included balloon angioplasty after stent
- Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edemahttps://reachmd.com/news/interleukin-6-inhibition-with-vamikibart-for-uveitic-macular-edema/2487788/Key Takeaways Intravitreal vamikibart was associated with week 12 improvement in visual acuity and retinal thickness across all three dose groups. Ocular adverse events were reported in 19 of 37 participants, with one unrelated serious event, one treat
- Parent Mental Health Interventions in the NICUhttps://reachmd.com/news/parent-mental-health-interventions-in-the-nicu/2487729/Key Takeaways The review included 160 studies, 16,639 parents, and 85 meta-analysis estimates assessing anxiety, depression, stress, and trauma symptoms with validated self-report questionnaires. Anxiety improved with bonding interventions, family-centered c
- Report: Dermatology M&A Momentum Sets Sights on Independent Practiceshttps://reachmd.com/news/dermatology-ma-momentum-continues-as-buyers-chase-independent-practices/2487714/Private equity investment in dermatology continues at a rapid pace in 2026, with buyer demand remaining strong despite more than a decade of consolidation across the specialty, according to a new market update from Physician Growth Partners.
- Consensus Panel Offers First Standardized Imaging Framework for High-Risk CSCChttps://reachmd.com/news/consensus-panel-offers-first-standardized-imaging-framework-for-high-risk-cscc/2487708/A multidisciplinary panel of experts has developed consensus recommendations to help standardize staging and surveillance imaging for patients with localized cutaneous squamous cell carcinoma (cSCC), publishing the recommendations online in
- FDA Accepts sNDA for Roflumilast Cream 0.05% in Infants With ADhttps://reachmd.com/news/fda-accepts-snda-for-zoryve-cream-005-in-infants-with-atopic-dermatitis/2487703/The US Food and Drug Administration (FDA) anounced that it has accepted Arcutis Biotherapeutics' supplemental New Drug Application (sNDA) seeking to expand the indication for ZORYVE (roflumilast) cream 0.05% to include infants aged 3 to 24 months with mild to mode
- Teva Advances Anti-IL-15 Antibody Into Phase 2b for Vitiligohttps://reachmd.com/news/teva-advances-anti-il-15-antibody-into-phase-2b-for-vitiligo/2487696/Teva Pharmaceutical Industries Ltd. has announced plans to advance its investigational anti-interleukin-15 (IL-15) monoclonal antibody (TEV-'408) into a Phase 2b clinical trial for non-segmental vitiligo (NSV) in the fourth quarter of 2026 following encouraging in
- Global Survey Highlights Widespread Skin Quality Concerns and Emotional Impacthttps://reachmd.com/news/global-survey-highlights-widespread-skin-quality-concerns-and-emotional-impact/2487693/A new global survey commissioned by Galderma found that skin quality concerns are nearly universal, with 9 in 10 respondents reporting at least 1 concern during the previous month and most experiencing an average of 2 concerns.1 The survey included more than 11,000 participants
- Otsuka Reports Two-Year VISIONARY EGFR Results in IgA Nephropathyhttps://reachmd.com/news/otsuka-reports-two-year-visionary-egfr-results-in-iga-nephropathy/2487671/Key Takeaways The topline readout centered on eGFR and was described as showing statistically significant kidney-function stabilization versus placebo over two years, with evidence of improvement. VOYXACT was characterized as well tolerated, with a fav